Furthermore, secondary BC survival differences by tumor receptor status were evident in middle- and older-aged women, with the largest impact seen in hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative disease. The gene discussed is NR4A1; the disease is breast cancer.